ASX Announcement

Medibio Limited – 9th April 2020



FINAL COMPASS PILOT COMPLETED SUCCESSFULLY

- The fourth and final ilumen™ pilot with Compass Group PLC has successfully been completed.
- Voluntary Participation rates across all four pilots were excellent, ranging from 60% to 71% of the targeted workforce
- These pilot programs have provided valuable insights for our discussion with the Compass Group regarding an ongoing relationship for ilumen™.

Melbourne, Australia and Minneapolis, MN – 9 April 2020: Medibio Limited (MEB or the Company) (ASX: MEB) (OTCPINK: MDBIF), a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions, is pleased to announce that the final Compass pilot has successfully been completed.

ilumen[™] has now been piloted in the following Compass divisions:

| | | Participation Rate (Voluntary) |
|--|--------------|--------------------------------------|
| Financial Services Division - UK | August '19 | 60% |
| Offshore and Remote Division - UK | October '19 | 71% |
| Offshore and Remote Division - Australia | October '19 | 65% |
| Defence Division - UK | February '20 | 68% |

Medibio has presented the results from the pilot programs to Compass management. The results were very well received and provided Compass management with unique insights into employee wellbeing. Importantly, during the pilots ilumen™ was able to identify hours of lost productivity of the participant cohort and an estimate of the related costs to Compass. ilumen™ also provided Compass with deidentified data on a number of key mental health metrics which could be filtered by location, department and demographics factors.

Most importantly, ilumen™ was able to identify Compass employees that were at high risk. Those employees received a confidential, personalized email recommending that they see a doctor, contact their Employee Assistance Program or access other assistance. Employees at high risk were not identified to Compass management.

Medibio is pleased to be assisting Compass in their efforts to ensure as much as possible, the mental wellbeing of its workforce. Medibio is now in meaningful discussions regarding the ongoing implementation of ilumen TM .


- ENDS -

This announcement is authorised for release to the market by the Board of Directors of Medibio Limited.

Level 4, 100 Albert Road, South Melbourne, Vic 3205 Email: info@medibio.com.au | www.medibio.com.au | <a

ACN: 008 130 336

ASX Announcement





About Medibio Limited

Medibio (ASX: MEB) (OTCPINK: MDBIF) is a health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. Through their Corporate Health product, the Company offers mental well-being solutions for businesses and are also developing products to serve the healthcare provider market. The company was founded in Australia, with offices located in Melbourne (Vic) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTC Pink Open Market. Investors can find additional information on www.otcmarkets.com and www.asx.com.au.

Further Information:

Medibio Investor and Media Enquiries:

Peter Taylor

NWR Communications

peter@nwrcommunications.com.au

T: +61 (0) 412 036 231

Level 4, 100 Albert Road, South Melbourne, Vic 3205 Email: <u>info@medibio.com.au</u> | <u>www.medibio.com.au</u>

ACN: 008 130 336